Dianthus Therapeutics Says Phase 3 CAPTIVATE Trial In CIDP Now Needs Fewer Than 200 Patients In Part A; Part A Results By End-2027, Part B By End-2028
Share
Why It Matters
Dianthus shrunk its trial to need fewer patients for approval. Watch if they hit their timeline goals and stay on budget.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.